Abstract
What is known and objectiveNeoadjuvant chemotherapy refers to systemic chemotherapy before implementing local treatment methods such as surgery or radiotherapy, and Neoadjuvant chemotherapy combined with aspirin have protective effect on preventing breast cancer patients. This study aims to investigate the role of aspirin in with breast cancer patients receiving neoadjuvant chemotherapy by targeting JAK2/STAT3. MethodsThis clinical study totally includes 200 participants, and these participants are divided into following two groups: control group (asprin, experimental group (asprin + neoadjuvant chemotherapy). Participants’ general data are collected and analyzed. The JAK2 protein levels, STAT3 protein levels in the tissue samples from control group and experimental group are determined by ELISA and immunohistochemistry. ResultsThe total of 200 participants are included in this study. Compared to the JAK2 level, STAT3 level in control group, the JAK2 level, STAT3 level in experimental group are significantly decreased and the difference is significant statistical difference(P < 0.05).Conclusions: aspirin in with breast cancer patients receiving neoadjuvant chemotherapy can suppress the development of breast cancer through up-regulated of JAK2 protein levels, STAT3 protein levels.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Journal of Radiation Research and Applied Sciences
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
